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explain the dependence of hypertrophy 
on PI3K, p21 has roles beyond that of 
cell-cycle inhibition depending on the 
cellular stress and environment. One of 
the original descriptions of p21 was as 
an inducer of cellular senescence,18 and 
p21 deletion was shown to prolong the 
lifespan of telomerase-defi cient cells and 
mice,19 a condition associated with short-
ened lifespan in humans and in mice. 
Coincidently, p21 but not p16 (another 
cyclin-dependent inhibitor) was found 
to be involved in telomere shortening-
induced senescence of human cells,20 
and transduction of p21 but not of p16 
caused hypertrophy in renal proximal 
tubule cells.11 Perhaps the consequences 
of renal hypertrophy and the fibrotic 
changes associated with aging are both 
controlled by the same PI3K/Akt/p21 
pathways. Th ese possibilities should be 
fruitful areas for future investigations.
In summary (Figure 1), both p21 and 
the PI3K/Akt pathways have been shown 
to be associated with cellular and organ 
hypertrophy. Th e work of Chuang et al.13 
reiterates this concept and at the same 
time shows that these pathways may be 
mutually interdependent. More work is 
needed to support these interactions and 
to elucidate fully the pathway of hyper-
trophy. At the same time, however, this 
work has pointed out possible interven-
tion strategies, by PI3K/Akt inhibition, to 
ameliorate hypertrophy.
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Membranous nephropathy: When 
and how to treat
KN Lai1
The treatment of idiopathic membranous nephropathy is heavily 
debated because of wide variation in outcome. A rational treatment 
strategy is needed to appropriately administer conservative treatment 
to the low-risk group but immunosuppressive therapy to those with 
medium or high risk of renal deterioration. Currently, combinations 
of steroids with alkylating agents are best studied. Newer forms of 
immunosuppressive treatment are currently under study. 
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Idiopathic membranous nephropathy 
(IMN) is a common cause of the nephrotic 
syndrome in adult patients. Th e treatment 
of patients with IMN has been a regular 
theme for debate. Today, once the diagno-
sis is made, symptomatic management for 
proteinuria and hypertension is mandated 
in almost all patients. Th e impact of these 
treatments alone on the natural history is 
expected to be positive but is diffi  cult to 
delineate distinctly. Th is wide variation 
in outcome is one of the factors that have 
led metaanalysis and systematic reviews of 
this disease to reach varying conclusions 
about the impact of immunosuppressive 
treatment on patient and renal survival 
and on remission rate of proteinuria.
Reports of the natural history of IMN 
are divergent and thus have set the stage 
for heavy disputes on the use of immuno-
suppressive therapy. Th e spectrum varies 
from a relatively benign course of 65% 
spontaneous remission of proteinuria and 
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an estimated renal survival rate of 88% in 
untreated patients at 5 years to a poor out-
come with corresponding rates of 33% and 
60%, respectively, in untreated patients at 
10 years. Th e diff erence lies in the hetero-
geneity of the patients. Outcome in non-
nephrotic patients with IMN invariably 
is good, with reported 10-year renal sur-
vival rates approximating 100% (reviewed 
by du Buf-Vereijken et al.1). In contrast, 
du Buf-Vereijken and co-workers1 had 
found that nearly half the patients with 
IMN and nephrotic syndrome developed 
renal failure aft er exclusion of non-neph-
rotic patients in their analysis of the natu-
ral history. Hence, the identifi cation of 
parameters that bear poor prognostic out-
come is important for selecting patients to 
receive appropriate immunosuppressive 
therapy. Apparently, our ability to predict 
those who are most likely to progress has 
improved. Male gender, increasing age, 
nephrotic-range proteinuria, the ratio 
of IgG to α1-microglobulin excretion in 
urine, focal segmental glomerulosclero-
sis, and impaired renal function at presen-
tation are predicting factors for risk of 
renal progression in IMN.2 It is, there-
fore, logical to adopt a more aggressive 
approach in immunosuppressive therapy 
for those patients with medium to high 
risk, whereas a symptomatic approach 
is appropriate for those with low risk of 
renal progression. Obviously, conservative 
treatment of patients with proteinuria has 
changed dramatically in the past decade 
with statins and angiotensin-converting 
enzyme inhibitors (ACEIs) or angiotensin 
receptor blockers (ARBs). Th e ACEIs or 
ARBs decrease proteinuria and attenuate 
renal progression in patients with dia-
betic and nondiabetic proteinuric renal 
diseases. However, the benefi cial eff ect 
of ACEIs or ARBs in improving the long-
term prognostic outcome in IMN remains 
to be proven.
In late 1960s, IMN was considered a 
slowly progressive disease that was totally 
unresponsive to steroid treatment. Two 
subsequent randomized controlled trials 
(RCTs) unequivocally proved that steroid 
alone in limited dosage or during a limi-
ted period did not prevent deterioration 
in renal function.3,4 It is possible that a 
higher dose of steroid administered for 
a longer period may be more eff ective, 
but the side eff ects are considerable. A 
subsequent approach devised to reduce 
the steroid toxicity was to use the steroid-
sparing property of immunosuppressive 
agents. Th e best study on the effi  cacy of 
combining an alkylating agent and pred-
nisone in patients with IMN undoubtedly 
is the RCT conducted by Ponticelli and 
co-workers from Italy.5 Nephrotic patients 
with IMN and normal renal function were 
randomized for treatment with alternat-
ing monthly cycles of prednisone and 
chlorambucil versus no treatment. Th e 
duration of treatment was 6 months. A 
long-term benefi cial eff ect of immuno-
suppressive therapy was demonstrated 
when these patients were followed up for 
more than 10 years. Treatment increased 
the remission rate (at the end of follow-
up, 63% versus 33%) and improved renal 
survival (92% versus 60%). In the recently 
published Cochrane metaanalysis,6 results 
provided by the study of Ponticelli and 
co-workers5 are virtually cancelled out 
by reports of three other RCTs. However, 
the sample size and follow-up duration of 
these RCTs were small and limited. Nota-
bly, these studies documented signifi cantly 
lower proteinuria in treated patients. Th e 
effi  cacy of alkylating agents in patients 
with IMN is supported by other studies 
that again are far from conclusive either 
because of a small sample size or because 
of the use of historical controls for com-
parison.6 More importantly, these studies 
included only patients with renal impair-
ment representing those with an unfavo-
rable renal prognosis and low likelihood 
of spontaneous remissions. Hence, one 
may be tempted to consider immunosup-
pressive therapy consisting of alkylating 
agents and prednisone as an acceptable 
therapy for patients with IMN.
Because of the side effects and the 
observation that disease activity may still 
progress aft er 6-month therapy of alkyla-
ting agents and prednisone, other classes 
of immunosuppressive agents have been 
used in the treatment of patients with 
IMN. Th ese include cyclophosphamide, 
cyclosporine (CsA), mycophenolate 
mofetil (MMF), tacrolimus (FK506), 
and, most recently, the anti-CD20 mono-
clonal antibody rituximab. Relevant data 
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Figure 1 | Treatment algorithm for idiopathic membranous nephropathy. ACEI, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CsA, 
cyclosporine; FK506, tacrolimus; MMF, mycophenolate mofetil; RFT, renal function test; Up, urinary 
protein.
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from the most important studies are well 
summarized in a recent review.1 It should 
be noted that no randomized trials of suf-
fi cient patient number have compared the 
various classes of agents, and therefore it 
is diffi  cult to draw hard conclusions. So 
far, there are no good data to suggest that 
rituximab is eff ective in patients at risk for 
renal progression. Many studies showed 
the short-term antiproteinuric eff ect of 
CsA in patients with IMN. Most inves-
tigators agree that the effect is evident 
within 3 months aft er the start of therapy, 
and that continued use of CsA beyond 
4 months is not useful in non-respond-
ers. It remains unclear whether use of 
CsA could have long-term benefi ts. In a 
small RCT of 18 patients with IMN and 
renal impairment, Cattran and co-work-
ers7 observed attenuation of renal dete-
rioration in CsA therapy compared with 
placebo. However, treatment with CsA did 
not result in improvement in renal func-
tion, and no patient developed complete 
remission of proteinuria, in contrast to 
observed eff ects of alkylating agents. CsA 
failed to exert long-term benefi ts in the 
Cyclosporine in Membranous Nephropa-
thy Study Group, comparing CsA with 
conservative treatment in patients with 
IMN and renal function deterioration 
(R Pisoni et al., J Am Soc Nephrol 2000; 
11: 0514A, abstr.). Th e situation may be 
diff erent in patients with no renal impair-
ment. Th e effi  cacy of CsA was studied in 
an RCT of patients with IMN and nor-
mal renal function yet steroid-resistant 
(steroid for 8 weeks only).8 CsA treat-
ment (26 weeks) signifi cantly decreased 
proteinuria as compared with placebo. 
However, after the end of treatment, 
many relapses occurred, and at the end of 
follow-up, diff erences in remission rates 
were not impressive. Furthermore, the 
potential nephrotoxicity may necessitate 
dose reduction.
Praga and co-workers9 (this issue) now 
report a multicenter study of 48 Spanish 
patients with IMN to study the therapeutic 
eff ect of tacrolimus (FK506). Patients were 
initially treated by ACEI or ARB for at 
least 2 months before being randomized 
to either a treatment or a no-treatment 
group. A higher incidence of complete 
recovery and partial recovery was noticed 
in the treatment group. The relapse 
rate was 47% by 18 months following 
the cessation of treatment. FK506 is a 
calcineurin inhibitor similar to CsA that 
has intrinsic nephrotoxicity. Caution must 
be exercised before one is convinced that 
FK506 is the preferred treatment for IMN. 
Comparing FK506 with no treatment 
gives less convincing evidence, as previous 
studies had documented the superiority 
of improving symptoms with most 
forms of immunosuppressive treatment. 
Comparison between FK506 and 
corticosteroid/cytotoxic agent treatment 
is preferred to determine whether 
FK506 is as good as or better than the 
present regime. Up to 30% spontaneous 
remission occurs in IMN patients; though 
more common in the fi rst 2 years aft er 
presentation, it can occur at any time. 
An observed period of 9 months may 
arguably still be short. Th e response rate 
and relapse rate were no better than with 
the steroid/cytotoxic agent regime. Th e 
relapse rate of corticosteroid/cytotoxic 
agent treatment is 32%, and that of CsA 
treatment is 30%–40%, by 2 years. Lastly, 
the long-term renal survival is not known 
for this group of patients receiving FK506, 
as the follow-up period remains short.
Th e recent reports of use of MMF will 
also be attractive if steroid/cytotoxic 
agent treatment fails, as the side eff ects 
of MMF are defi nitely less than those of 
FK506 or CsA. Experience with MMF 
in patients with IMN is limited and 
inconclusive. Miller and co-workers10 
treated 16 patients with IMN of whom 
the majority were high-risk with evi-
dence of renal failure, using MMF in 
dosages of 0.5 to 2 g per day for periods 
between 2 and 10 months. Partial remis-
sion of proteinuria was achieved in only 
two patients. In contrast, a pilot study 
of Dutch patients with IMN and renal 
insufficiency using a combination of 
steroid and MMF (2 g per day) for 1 year 
achieved a signifi cant decrease in serum 
creatinine and proteinuria.1
Finally, what have we learned, from 
numerous previous studies and metaanal-
ysis, about how to manage patients with 
IMN? As a recent review2 suggests, we 
should stratify patients into diff erent cate-
gories in regard to their risk for progres-
sion to chronic renal failure. A treatment 
algorithm is shown in Figure 1. In only 
a small proportion of high-risk patients 
with IMN, a longer duration of combina-
tion of corticosteroid and cytotoxic agents 
should be taken as the treatment standard. 
When this regime fails or undesirable side 
eff ects occur, other immunosuppressive 
therapy such as CsA, FK506, or MMF may 
be an alternative.
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